Zacks Investment Research on MSN1d
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...
Q1 EPS Forecast for Jazz Pharmaceuticals Raised by Analyst
Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for shares of Jazz Pharmaceuticals in a ...
Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $187.71
Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) have received a consensus rating of “Moderate Buy” from ...
Fierce Biotech4d
Chimerix engaged with 7 other biopharmas before choosing Jazz's $935M deal—here's why it won
Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...
TPB, ACB and JAZZ: Three Pot Stocks Flowering With Potential Upside
After bursting onto the scene several years ago with considerable fanfare, much of the hype about cannabis stocks has quietly died down, and ...
Endpoints News4d
The buildup to Chimerix's $935M ex­it to Jazz, with more than half a dozen par­ties in­trigued
Chimerix began attracting deal interest in its experimental brain tumor treatment about 18 months before it signed a $935 ...
Bank of America Securities Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a ...